CompletedPhase 2NCT01666444
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Studying OBSOLETE: Primary peritoneal serous/papillary carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene
- Principal Investigator
- Bradley J. Monk, MDSt. Joseph's Hospital and Medical Center, Phoenix AZ
- Intervention
- pegylated liposomal doxorubicin (PLD)(drug)
- Enrollment
- 297 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2012 – 2016
Study locations (30)
- St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States
- Providence Saint Joseph Medical Center, Burbank, California, United States
- Kaiser Permanente Medical Center, Hayward, California, United States
- Long Beach Memorial Medical Center, Long Beach, California, United States
- Kaiser Permanente Medical Center, Oakland, California, United States
- Kaiser Permanente Medical Center, Roseville, California, United States
- Sutter Cancer Center, Sacramento, California, United States
- Kaiser Permanente Medical Center, Sacramento, California, United States
- Kaiser Permanente Medical Center, San Francisco, California, United States
- Kaiser Permanente Medical Center, San Jose, California, United States
- Kaiser Permanente Medical Center, Santa Clara, California, United States
- Kaiser Permanente Medical Center, South San Francisco, California, United States
- Stanford University School of Medicine, Stanford, California, United States
- Kaiser Permanente Medical Center, Vallejo, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Gynecologic Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01666444 on ClinicalTrials.govOther trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06856499Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerUniversity of Colorado, Denver
- RECRUITINGPHASE3NCT06994195A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian CancerSichuan Baili Pharmaceutical Co., Ltd.
- RECRUITINGPHASE2NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesAbbVie
- RECRUITINGNANCT06969833Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube CarcinomaCentre Oscar Lambret
- RECRUITINGPHASE3NCT05659381Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerGOG Foundation
- RECRUITINGNANCT05597683Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal ChemotherapyGangnam Severance Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05456685Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerAbbVie
- RECRUITINGPHASE3NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Genelux Corporation
See all trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma →